Presentation is loading. Please wait.

Presentation is loading. Please wait.

Pathophysiology of Non-Communicable Diseases in Treated HIV Infection: Is there a common path? Peter W. Hunt, MD Associate Professor of Medicine Division.

Published byLogan Patterson Modified over 8 years ago

Similar presentations

Presentation on theme: "Pathophysiology of Non-Communicable Diseases in Treated HIV Infection: Is there a common path? Peter W. Hunt, MD Associate Professor of Medicine Division."— Presentation transcript:

1 Pathophysiology of Non-Communicable Diseases in Treated HIV Infection: Is there a common path? Peter W. Hunt, MD Associate Professor of Medicine Division of Experimental Medicine University of California San Francisco

2 Legarth/Obel, JAIDS, 2016 HIV- Controls 1996-2014 HIV+ 2006-2014 2000-2005 1996-2000 ~20 year shorter if CD4 nadir <350 (Samji, PLoS One, 2013) 10y Decreased Life Expectancy in Older HIV+ Adults in Modern ART Era Danish Cohort

3 Many age-associated morbidities also increased in treated HIV Cardiovascular disease [1-3] Cardiovascular disease [1-3] Cancer (non-AIDS) [4] Cancer (non-AIDS) [4] Bone fractures / osteoporosis [5,6] Bone fractures / osteoporosis [5,6] COPD [12] COPD [12] Liver disease [7] Liver disease [7] Kidney disease [8] Kidney disease [8] Cognitive decline [9] Cognitive decline [9] Non-AIDS infections [10] Non-AIDS infections [10] Frailty [11] Frailty [11] 1. Freiberg, M., et al. JAMA Int Med. 2013;173(8):614-22. 2; Tseng, Z, et al. JACC. 2012;59(21):1891-6. 3. Grinspoon SK, et al. Circulation. 2008;118:198-210. 4. Silverberg, M., et al. AIDS, 2009;23(17):2337-45. 5. Triant V, et al. J Clin Endocrinol Metab. 2008;93:3499-3504. 6. Arnsten JH, et al. AIDS. 2007 ;21:617-623. 7. Odden MC, et al. Arch Intern Med. 2007;167:2213-2219. 8. Choi A, et al. AIDS, 2009;23(16):2143-49. 9. McCutchan JA, et a. AIDS. 2007 ;21:1109-1117. 10. Sogaard, CID, 2008; 47(10): 1345- 53. 11. Desquilbet L, et al. J Gerontol A Biol Sci Med Sci. 2007;62:1279-1286; 12 Attia, Chest,2014

4 Potential Role of Inflammation in Driving Morbidity in Older HIV+ Individuals Lifestyle ART Toxicity Persistent Inflammation Age- associated Morbidity Deeks and Phillips, BMJ, 2009

5 Rhesus Macaque Infect with SIV High Levels of Viral Replication AIDS and death Silvestri, Immunity, 2003 An Important Clue from Nature Minimal Immune Activation Massive Immune Activation Sooty Mangabey Infect with SIV High Levels of Viral Replication No AIDS, normal lifespan

6 T Cell Activation Remains Abnormally High During ART-mediated Viral Suppression Hunt, JID, 2003 & PLoS One, 2011; see also: Neuhaus, JID 2010; Wada, AIDS 2014) Innate Immune Activation and Inflammation also Remain Abnormal

7 A single measurement of IL-6 or D-dimer predicts morbidity/mortality over next 10y Grund, PLoS One, 2016, #60; see also: Ledwama, PLoS One, 2012

8 Inflammation Predicts Disease in Treated HIV Infection Mortality (Kuller, PLoS Med, ‘08; Tien, JAIDS, ‘10; Justice, CID ‘12; Hunt, JID ‘14) Cardiovascular Disease (Duprez, Atherosclerosis, 2009) Cancer (Breen, Cancer Epi Bio Prev, 2010; Borges, AIDS, 2013) Venous Thromboembolism (Musselwhite, AIDS, 2011) Type II Diabetes (Brown, Diabetes Care, 2010) COPD (Attia, Chest, 2014) Renal Disease (Gupta, HIV Med, 2015) Bacterial Pneumonia (Bjerk, PLoS One, 2014) Cognitive Dysfunction (Burdo, AIDS, 2013; Letendre CROI 2012) Depression (Martinez, JAIDS, 2014) Frailty (Erlandson, JID, 2013)

9 What can we do to reverse immune activation during suppressive ART now?

10 Smoking increases monocyte activation (Valiathan, PLoS One, 2014) Hazardous EtOH associated with ↑ sCD14 / microbial translocation (Carrico, Alc Clin Exp Res, 2015) Methamphetamine use increases immune activation and suppresses T cell function (Massanella, Sci Reports, 2015) Obesity associated with increased inflammation (Koethe, ARHR, 2013) Moderate exercise decreases inflammation (Longo, CROI 2014, #763; Dirajlal-Fargo, Antiviral Therapy, 2016) Lifestyle Factors Contribute to Immune Activation in Treated HIV

11 Interventions on the Horizon?

12 Statins Decrease Immune Activation and Aortic Plaque in Treated HIV Infection sCD14 Declines with Rosuvastatin Plaque Regression with Atorvastatin Funderburg/McComsey, JAIDS, 2015Lo/Grinspoon, Lancet HIV, 2015 REPRIEVE Trial of Pitavastatin (n=6500) Now Enrolling! See also: Nakanjako, Trop Med Int Health, 2015

13 How do we develop more effective interventions?

14 Immune Activation As a Tree www.ulead.org Roots HIV reservoirs CMV Microbial translocation Branches IL-6 / Inflammation D-dimer / Coagulation Lymphoid Fibrosis Leaves End-organ diseases

15 Individual Roots and Branches: The Whack-a-Mole Problem TLR Inhibition with Chloroquine ↑ HIV VL Jacobson for A5258 Team, ARHR, 2016

16 Can we find the tree trunk? www.ulead.org Roots HIV reservoirs CMV Microbial translocation Branches Inflammation Coagulation Lymphoid Fibrosis Trunk IL-1b Jak/Stat IDO-1 Monocyte activation

17 Despite optimal ART, HIV shortens life expectancy and ↑ age-associated morbidities. Immune activation / inflammation persist despite ART and may predict these morbidities. Lifestyle interventions are important! Statins show promise in decreasing immune activation (await REPRIEVE) Need better interventions for roots (HIV, CMV, microbial translocation) and perhaps “tree trunk” Summary

18 Acknowledgements Core Immunology Lab/DEM Elizabeth Sinclair Lorrie Epling Jeff Milush Mike McCune SFGH Cardiology Priscilla Hsue UARTO Helen Byakwaga Priscilla Martinez Alex Tsai Sheri Weiser David Bangsberg Mark Siedner NIAID/VRC Jason Brenchley Danny Douek SCOPE/OPTIONS/UCSF Sulggi Lee Ma Somsouk Steve Deeks Jeff Martin Hiroyu Hatano Vivek Jain Rick Hecht Chris Pilcher Rebecca Hoh SCOPE and OPTIONS Teams UCSF Drug Studies Unit Yong Huang CWRU Michael Lederman Nick Funderburg Mike Freeman R01AI110271, R56AI100765, 1R21AI087035, 1R21AI07877, DDCF CSDA, CHRP IDEA Award; Roche, Inc.

Download ppt "Pathophysiology of Non-Communicable Diseases in Treated HIV Infection: Is there a common path? Peter W. Hunt, MD Associate Professor of Medicine Division."

Similar presentations

Impact of Tryptophan Catabolism on CD4+ T Cell Recovery and Mortality in HIV-infected Ugandans Initiating ART Peter W. Hunt, Sheri Weiser, Yong Huang,

Impact of Tryptophan Catabolism on CD4+ T Cell Recovery and Mortality in HIV-infected Ugandans Initiating ART Peter W. Hunt, Sheri Weiser, Yong Huang,
Www.aids2014.org HCV cure: new treatment paradigms for HCV infection Sanjay Bhagani Consultant Physician/Senior Lecturer Royal Free Hospital/UCL London.

HCV cure: new treatment paradigms for HCV infection Sanjay Bhagani Consultant Physician/Senior Lecturer Royal Free Hospital/UCL London.
Interventions to Reduce Inflammation and Immune Activation in Treated HIV Infection Peter W. Hunt, MD Assistant Professor of Medicine UCSF HIV/AIDS Division.

Interventions to Reduce Inflammation and Immune Activation in Treated HIV Infection Peter W. Hunt, MD Assistant Professor of Medicine UCSF HIV/AIDS Division.
Should we treat HIV Controllers ? IAS 2013 Pr Olivier Lambotte Department of internal medicine and clinical immunology Bicêtre Hospital, University Paris.

Should we treat HIV Controllers ? IAS 2013 Pr Olivier Lambotte Department of internal medicine and clinical immunology Bicêtre Hospital, University Paris.
Offering ARV Treatment to All HIV-infected Persons in San Francisco Grant Colfax, MD Director of HIV Prevention and Research San Francisco Department of.

Offering ARV Treatment to All HIV-infected Persons in San Francisco Grant Colfax, MD Director of HIV Prevention and Research San Francisco Department of.
The role of HIV infection and Co-infections in Serious Non-AIDS Events Peter W. Hunt, M.D Associate Professor of Medicine, UCSF.

The role of HIV infection and Co-infections in Serious Non-AIDS Events Peter W. Hunt, M.D Associate Professor of Medicine, UCSF.
The pathogenesis of persistent HIV-associated inflammation during long-term antiretroviral therapy Steven G. Deeks Professor of Medicine University of.

The pathogenesis of persistent HIV-associated inflammation during long-term antiretroviral therapy Steven G. Deeks Professor of Medicine University of.
Why may non-communicable diseases occur more often in those with HIV infection? Suzanne Crowe Co-Head Centre for Virology, Burnet Institute Consultant.

Why may non-communicable diseases occur more often in those with HIV infection? Suzanne Crowe Co-Head Centre for Virology, Burnet Institute Consultant.
Slide 1 of 11 From CB Hicks, MD, at Chicago, IL: May 20, 2013, IAS-USA. IAS–USA Charles B. Hicks, MD Professor of Medicine Duke University Medical Center.

Slide 1 of 11 From CB Hicks, MD, at Chicago, IL: May 20, 2013, IAS-USA. IAS–USA Charles B. Hicks, MD Professor of Medicine Duke University Medical Center.
Www.ias2011.org Aging with HIV infection Bill Powderly MD School of Medicine and Medical Sciences University College Dublin Ireland.

Aging with HIV infection Bill Powderly MD School of Medicine and Medical Sciences University College Dublin Ireland.
Why is inflammation elevated in treated HIV infection and why does it matter? Steven G. Deeks Professor of Medicine University of California, San Francisco.

Why is inflammation elevated in treated HIV infection and why does it matter? Steven G. Deeks Professor of Medicine University of California, San Francisco.
Cardiovascular Complications of HIV Mark Boyd MD, FRACP The Kirby Institute for infection and immunity in society 7 th IAS Conference Kuala Lumpur, Malaysia.

Cardiovascular Complications of HIV Mark Boyd MD, FRACP The Kirby Institute for infection and immunity in society 7 th IAS Conference Kuala Lumpur, Malaysia.
Marian Kerbleski, RN UCSF AIDS Division San Francisco General Hospital.

Marian Kerbleski, RN UCSF AIDS Division San Francisco General Hospital.
Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis Priscilla Y. Hsue, Peter W. Hunt, Jeffrey N. Martin, Amanda Schnell,

Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis Priscilla Y. Hsue, Peter W. Hunt, Jeffrey N. Martin, Amanda Schnell,
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER CROI 2015: Hot Topics in HIV Primary Care Brian R. Wood, MD Assistant Professor of Medicine, University.

N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER CROI 2015: Hot Topics in HIV Primary Care Brian R. Wood, MD Assistant Professor of Medicine, University.
2014 “Towards an HIV Cure” symposium Melbourne The Immune Checkpoints PD-1, LAG-3 and TIGIT are Biomarkers of HIV Infected Cells During ART and Identify.

2014 “Towards an HIV Cure” symposium Melbourne The Immune Checkpoints PD-1, LAG-3 and TIGIT are Biomarkers of HIV Infected Cells During ART and Identify.
Slide 1 of 24 From DC Douek, MD, at San Francisco, CA: March 24, 2013, IAS-USA. IAS–USA Daniel C. Douek, MD, PhD Bethesda, Maryland Immune Activation,

Slide 1 of 24 From DC Douek, MD, at San Francisco, CA: March 24, 2013, IAS-USA. IAS–USA Daniel C. Douek, MD, PhD Bethesda, Maryland Immune Activation,
Cardiovascular Disease: Predicting Risk and Monitoring Outcomes Monica R. Shah, MD, FACC NHLBI AIDS Coordinator Conference on Retroviruses and Opportunistic.

Cardiovascular Disease: Predicting Risk and Monitoring Outcomes Monica R. Shah, MD, FACC NHLBI AIDS Coordinator Conference on Retroviruses and Opportunistic.
Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity Peter W. Hunt, MD Associate Professor of Medicine UCSF HIV/AIDS Division.

Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity Peter W. Hunt, MD Associate Professor of Medicine UCSF HIV/AIDS Division.
NCD Complications in HIV Patients Esteban Martinez Hospital Clínic University of Barcelona Barcelona SPAIN Washington D.C., USA,

NCD Complications in HIV Patients Esteban Martinez Hospital Clínic University of Barcelona Barcelona SPAIN Washington D.C., USA,

Similar presentations

Ads by Google